Several RNA viruses, including SARS-CoV-2, can infect or use the eye as an entry portal to cause ocular or systemic diseases.
Povidone-Iodine (
PVP-I) is routinely used during ocular surgeries and eye banking as a cost-effective
disinfectant due to its broad-spectrum antimicrobial activity, including against viruses. However, whether
PVP-I can exert
antiviral activities in virus-infected cells remains elusive. In this study, using Zika (ZIKV) and Chikungunya (CHIKV)
virus infection of human corneal and
retinal pigment epithelial cells, we report
antiviral mechanisms of
PVP-I. Our data showed that
PVP-I, even at the lowest concentration (0.01%), drastically reduced viral replication in corneal and
retinal cells without causing cellular toxicity.
Antiviral effects of
PVP-I against ZIKV and CHIKV were mediated by direct viral inactivation, thus attenuating the ability of the virus to infect host cells. Moreover, one-minute
PVP-I exposure of infected ocular cells drastically reduced viral replication and the production of infectious progeny virions. Furthermore, viral-induced (CHIKV) expression of inflammatory genes (TNF-α, IL-6, IL-8, and IL1β) were markedly reduced in
PVP-I treated corneal epithelial cells. Together, our results demonstrate potent
antiviral effects of
PVP-I against ZIKV and CHIKV
infection of ocular cells. Thus, a low dose of
PVP-I can be used during
tissue harvesting for corneal transplants to prevent potential transmission of RNA viruses via infected cells.